Nurix Therapeutics (NRIX) Stock Forecast & Price Target
Score
Nurix Therapeutics, Inc. price target
| NRIX | |
|---|---|
| Low | $31.00 |
| Average | $35.58 |
| High | $45.00 |
| Upside vs current price | +129.8% |
The average target of $35.58 is +129.8% versus the current NRIX price of $15.48.
Nurix Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 5 |
| Buy | 8 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
14 analysts cover NRIX.
Nurix Therapeutics, Inc. EPS and revenue estimates
NRIX shows the next fiscal years with at least three analysts: 2026 EPS $2.35, 2027 EPS $-2.13. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $2.35 | $681.79M |
| 2027 | $-2.13 | $99.61M |
Is Nurix Therapeutics, Inc. a buy or sell?
Of the 14 analysts covering Nurix Therapeutics, Inc., 13 rate it a buy (5 strong buy and 8 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The NRIX consensus label is Buy, beside 13 buy-side ratings and 0 sell-side ratings.
The average target of $35.58 implies +129.8% versus the current price of $15.48.
Those 14 ratings on NRIX are a headcount, and the label on file is Buy.
Reading the Nurix Therapeutics, Inc. forecast
The NRIX target band runs from $31.00 to $45.00. The average inside that band is $35.58.
Set next to the $15.48 NRIX quote, that average is +129.8%.
Ratings on the Nurix Therapeutics, Inc. cluster: 13 of 14 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.
NRIX targets have not moved much: $35.50 recently, $35.50 across the quarter.
Only 14 analysts cover NRIX, so the average rests on a short list.
Nurix Therapeutics, Inc. forecast questions
What is the NRIX price target?
The published range for NRIX is $31.00 to $45.00, with an average of $35.58. That average is +129.8% versus the current price of $15.48.
Is Nurix Therapeutics, Inc. a buy or sell?
Of the 14 analysts covering Nurix Therapeutics, Inc., 13 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, and the NRIX headcount is 13 buy, 1 hold, and 0 sell.
What is the EPS estimate for Nurix Therapeutics, Inc.?
Analyst EPS estimates for Nurix Therapeutics, Inc.: 2026 $2.35, 2027 $-2.13.
What is the revenue estimate for Nurix Therapeutics, Inc.?
Analyst revenue estimates for Nurix Therapeutics, Inc.: 2026 $681.79M, 2027 $99.61M.
How many analysts cover NRIX?
14 analysts cover NRIX. Their consensus on NRIX is Buy, across those 14.